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OBJECTIVE — Insulin resistance is a suspected causative factor in a wide variety of diseases.
We aimed to determine whether insulin resistance, estimated by the homeostasis model assess-
ment for insulin resistance (HOMA-IR), is associated with all-cause or disease-speciﬁc mortality
among nondiabetic persons in the U.S.
RESEARCH DESIGN AND METHODS — We determined the association between
HOMA-IRanddeathcertiﬁcate–basedmortalityamong5,511nondiabetic,adultparticipantsof
the third U.S. National Health and Nutrition Examination Survey (1988–1994) during up to 12
years of follow-up, after adjustment for potential confounders (age, sex, BMI, waist-to-hip ratio,
alcohol consumption, race/ethnicity, educational attainment, smoking status, physical activity,
C-reactive protein, systolic and diastolic blood pressure, plasma total and HDL cholesterol, and
triglycerides).
RESULTS — HOMA-IR was signiﬁcantly associated with all-cause mortality (adjusted hazard
ratio1.16[95%CI1.01–1.3],comparingsuccessivequartilesofHOMA-IRinalinearmodeland
1.64 [1.1–2.5], comparing the top [HOMA-IR 2.8] to the bottom [HOMA-IR 1.4] quartile).
HOMA-IR was signiﬁcantly associated with all-cause mortality only in subjects with BMI 25.2
kg/m
2 (the median value) but not in subjects with BMI 25.2 kg/m
2. Subjects in the second,
third, and fourth quartile of HOMA-IR appeared to have higher cardiovascular mortality than
subjects in the lowest quartile of HOMA-IR. HOMA-IR was not associated with cancer-related
mortality.
CONCLUSIONS — HOMA-IR is associated with all-cause mortality in the nondiabetic U.S.
population but only among persons with normal BMI. HOMA-IR is a readily available measure
that can be used in the future to predict mortality in clinical or epidemiological settings.
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I
nsulin resistance is a condition in
which normal amounts of insulin are
not adequate to produce the expected
biologicresponseintargettissues,includ-
ing adipose tissue, muscle, and liver. In-
sulinresistancehasbeenassociatedwitha
wide variety of adverse health outcomes,
including type 2 diabetes (1), hyperten-
sion (2), cardiovascular disease (1), cere-
brovascular disease (3), peripheral
vascular disease (4), congestive heart fail-
ure (5), nonalcoholic fatty liver disease
(6), dyslipidemia (low HDL cholesterol
and high triglycerides) (7), and a variety
ofmalignancies(8).Usingamathematical
simulation model, Eddy et al. (9) recently
estimated that insulin resistance was re-
sponsible for 42% of myocardial infarc-
tions in the U.S. and was the most
important single cause of coronary artery
disease.
Obesity is known to be a strong risk
factor for insulin resistance, in particular
ectopic as opposed to subcutaneous adi-
posity (10). In addition, factors unrelated
to obesity are important contributors to
insulinresistance,suchasrace,sex,phys-
ical activity, and genetic factors, while as-
yet-unknown causes of insulin resistance
also likely exist.
The homeostasis model assessment
for insulin resistance (HOMA-IR) esti-
mates insulin resistance from fasting
plasma glucose and serum insulin levels
(11). There is good correlation between
valuesofinsulinresistanceobtainedusing
HOMA-IR and the euglycemic-hyperin-
sulinemic clamp method (12), the gold-
standard test that is too costly and
technically demanding to be used in epi-
demiologic studies or clinical practice.
Given the combination of accuracy and
easeoftesting,HOMA-IRisconsideredan
appropriate method for measurement of
insulin resistance in epidemiologic stud-
ies (12).
Our aim was to determine the associ-
ationbetweenHOMA-IRandmortalityin
nondiabetic people in the U.S. indepen-
dently of other important predictors of
mortality. This ﬁnding would be impor-
tant in incorporating HOMA-IR into fu-
ture models predicting mortality for
clinical or epidemiological purposes, es-
pecially since HOMA-IR is readily
available.
RESEARCH DESIGN AND
METHODS— Datawerederivedfrom
the Third National Health and Nutrition
Examination Survey (NHANES III), a
cross-sectional study conducted by the
National Center for Health Statistics
(NCHS) between 1988 and 1994 in order
to assess the health and nutritional status
of the noninstitutionalized U.S. popula-
tion (13). Participants completed per-
sonal, structured interviews at home and
then attended a mobile examination cen-
ter at 89 locations throughout the U.S.
NHANES III utilized a stratiﬁed, multi-
stage, probability cluster sampling design
to obtain a representative sample of the
civilian, noninstitutionalized population.
Non-Hispanic blacks, Mexican Ameri-
cans, and the elderly were deliberately
oversampled, in order to allow calcula-
tion of more precise estimates of the dis-
tribution of variables in these groups.
The NCHS created the NHANES III–
linked mortality ﬁle by linking NHANES
III with the National Death Index (14), a
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deaths in the U.S. since 1979. This ﬁle
linksNHANESIIIparticipants,aged17
years, with death records from the Na-
tional Death Index through 31 December
2000. National Death Index records pro-
vided data on date and underlying cause
of death. Linkage of NHANES III and Na-
tional Death Index records was per-
formed by probabilistic matching using
up to 12 identifying data items (15). A
selected sample of death certiﬁcates was
reviewed manually to validate the accu-
racy of the process. We studied the asso-
ciationsbetweenHOMA-IRascertainedat
baseline in NHANES III between 1988
and 1994 and mortality up to 31 Decem-
ber 2000, determined from the NHANES
III–linked mortality ﬁle.
NHANES III participants were as-
signed to morning, afternoon, or evening
examinations and were instructed to fast
for 10–16 h prior to the morning exami-
nation or for 6 h before the afternoon or
evening examination. The study was de-
signed such that the participants assigned
to the morning examination constituted a
nationallyrepresentativesample.Welim-
ited the current analysis to participants
assigned to the morning examination,
reasoning that there are systematic differ-
ences in serum insulin and plasma glu-
cose levels measured in the morning,
afternoon, or evening despite fasting. Of
7,959 participants aged 20 years as-
signed to the morning (10:00 A.M.) phle-
botomy and examination, we excluded
129 pregnant women; 483 participants
who fasted for 9o r24 h; and partic-
ipantswithmissingdataonseruminsulin
or plasma glucose levels (n  455), waist
circumference, or BMI (n  250); educa-
tional attainment (n  28); systolic or di-
astolic blood pressure (n  169); alcohol
consumption (n  209); and serum cho-
lesterol, HDL cholesterol, triglyceride
(n  94); and serum C-reactive protein
(n  46) levels. We excluded 344 partic-
ipantswithpreviouslydiagnoseddiabetes
and 237 with previously undiagnosed di-
abetes. Participants were deﬁned as hav-
ing previously diagnosed diabetes if they
reported “ever being told by a doctor that
they had diabetes or sugar diabetes other
than during pregnancy” or if they were
taking insulin or oral hypoglycemic med-
ications. Undiagnosed diabetes was de-
ﬁned as a fasting plasma glucose level
126 mg/dl among individuals without
diagnosed diabetes. Only four additional
participants did not have data linked to
the NHANES III mortality ﬁle, leaving
5,511participantsinthecurrentanalyses.
Determination of HOMA-IR
Fasting plasma glucose was measured us-
ing a modiﬁed hexokinase enzymatic as-
say (Cobas Mira Chemistry System;
Roche Diagnostic Systems, Montclair,
NJ). Fasting serum insulin was measured
by radioimmunoassay using a double-
antibody batch method (Pharmacia Insu-
lin RIA kit; Pharmacia Diagnostics,
Uppsala, Sweden). During the 6 years of
the study, the coefﬁcient of variation
ranged from 1.6 to 3.7% for the glucose
assay and 5.8 to 13.8% for the insulin
assay (16). We calculated HOMA-IR as
(fasting serum insulin [U/ml]  fasting
plasma glucose [mmol/l])/22.5 (12).
Ascertainment of mortality
Our primary outcome was all-cause mor-
tality. In secondary analyses, we consid-
ered whether HOMA-IR was associated
with mortality from cardiovascular dis-
eases or cancer, two conditions that have
been associated with insulin resistance
and that constitute the most important
causes of death in the U.S. population.
Cardiovascular mortality was deﬁned by
the presence of the following ICD-10
codes recorded as the underlying cause of
deathondeathcertiﬁcates:ischemicheart
diseases (I20–I25), atherosclerosis (I70),
heart failure (I50), and cerebrovascular
diseases (I60–69). Cancer mortality was
deﬁned by ICD-10 codes for malignant
neoplasms (C00–C97) and in situ neo-
plasms, benign neoplasms, and neo-
plasmsofuncertainorunknownbehavior
(D00–D48).
Risk variables and potential
confounders
We considered variables that may be as-
sociated with insulin resistance and/or
mortality as potential confounders in
multivariate models including age, sex,
BMI, waist-to-hip ratio, alcohol con-
sumption (categorized as none or 12
drinks in any year, 0–1 drink/day,
1–2 drinks/day, and 2 drinks/day on
average over the preceding 12 months),
race-ethnicity (categorized as non-
Hispanic white, non-Hispanic black,
Mexican American, and “other”), educa-
tional attainment (years of school com-
pleted), smoking status (never, former,
1 pack/day, 1 pack/day), C-reactive
protein (categorized as 0–0.3 and 0.3
mg/dl), physical activity (calculated by
multiplying each recreational and non-
recreational activity by its intensity value
andaddinguptheproductsforallactivity
types), systolic and diastolic blood pres-
sure, plasma total and HDL cholesterol,
andtriglycerides(thelastsixvariablescat-
egorizedintoquartilesasdummycategor-
ical variables).
Statistical analyses
Cox proportional hazards models (17)
were used to determine the hazard ratio
(HR) for mortality associated with
HOMA-IR. HOMA-IR was divided into
quartiles (1.4, 1.4–2.0, 2.0–2.8,
and 2.8) and modeled as a dummy cat-
egorical variable (each higher quartile
compared with the lowest quartile) or
modeled as the difference between suc-
cessive quartiles. HOMA-IR was also
modeled as a linear continuous variable.
The proportional hazards assumption
was examined using log plots of sur-
vival versus time. The date of the
NHANESIIIbaselineexamination,which
occurred for each participant at some
timebetween1988and1994,wasusedas
time zero. For participants who died be-
fore 31 December 2000, person-months
of follow-up were calculated from the ex-
amination date through the date of death.
For participants who were alive as of 31
December 2000, person-months of fol-
low-up were calculated from the examina-
tion date through the end of the mortality
follow-up period on 31 December 2000.
This variable, “describing the person-
months of follow-up” is provided by the
NCHS as part of the NHANES III mortality
ﬁles under the name “permth_exm.” For
analyses of cause-speciﬁc mortality, partic-
ipants who died of other causes were cen-
sored at the date of death.
We developed three models that si-
multaneously adjusted for the following
variables in the association between
HOMA-IR and mortality:
● Model 1: age and sex.
● Model 2: age, sex, BMI, and waist-to-
hip ratio.
● Model 3: age, sex, BMI, waist-to-hip ra-
tio, race/ethnicity, smoking, alcohol
consumption, physical activity, educa-
tion, systolic blood pressure, diastolic
bloodpressure,totalserumcholesterol,
serum HDL cholesterol, serum triglyc-
erides, and serum C-reactive protein.
We determined whether the association
betweenHOMA-IRandmortalitywasdif-
ferent among subgroups deﬁned by BMI,
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action terms and subgroup analyses.
NHANESIIIisbaseduponacomplex
sampling design that we took into ac-
count in statistical analyses using the sur-
vey commands of STATA statistical
software version 10 and the appropriate
weight (“wtpfhsd6,” speciﬁc for subjects
assigned to the morning examination),
strata (“sdpstra6”), and primary sampling
unit (“sdppsu6”) variables as recom-
mended in the NHANES III Analytical
Guidelines, such that our results are rep-
resentative of the U.S. population (18).
Taylor series linearization was used for
variance estimation. A two-sided P value
0.05 was a priori considered to be sta-
tistically signiﬁcant.
RESULTS— Higher HOMA-IR quar-
tiles were associated with greater mean
age, BMI, waist circumference, waist-to-
hipratio,plasmatotalcholesterol,plasma
triglycerides, systolic and diastolic blood
pressure, and with lower mean plasma
HDL cholesterol and physical activity
(Table 1). Subjects within higher
HOMA-IR quartiles were more likely to
have elevated serum C-reactive protein,
to be male, to have ethnicity other than
non-Hispanic white, and to consume lit-
tle or no alcohol.
In our analytical cohort of 5,511 par-
ticipants, 643 deaths occurred during a
mean follow-up of 8.5 years, including
237 deaths related to cardiovascular dis-
eases and 170 cancer-related deaths. In-
creasing HOMA-IR quartile was
signiﬁcantly associated with increasing
all-causemortalityafteradjustmentforall
potential confounders listed above (ad-
justed HR [AHR] 1.25 [95% CI 1.1–1.5],
comparing successive quartiles) (Table
2). Subjects in the top quartile of
HOMA-IR (2.8) had signiﬁcantly
greater mortality than subjects in the bot-
tom quartile (HOMA-IR 1.4) after ad-
justment for potential confounders (1.64
[1.1–2.5]). When HOMA-IR was mod-
eledasalinearcontinuousvariable,itwas
signiﬁcantly associated with mortality
(1.06[1.02–1.1],foreachunitincreasein
HOMA-IR).
We identiﬁed substantial interaction
between HOMA-IR and BMI in the asso-
ciation with mortality (P  0.05 for the
categorical interaction term). HOMA-IR
was signiﬁcantly associated with mortal-
ity among subjects with BMI below the
median level (25.2 kg/m
2) but not among
subjectswithBMI25.2kg/m
2(Table2).
The association between HOMA-IR and
mortality was similar in men and women
and in people with high or low waist-to-
hip ratio.
HOMA-IR was not associated with
Table 1—Baseline characteristics of participants by HOMA-IR quartile*
Characteristic
HOMA-IR
1.4 1.4–2.0 2.0–2.8 2.8
Age (years) 40.1  0.63 42.6  0.78 43.9  0.65 47.4  0.62
Education (years) 12.9  0.11 12.9  0.14 12.4  0.15 12.0  0.14
BMI (kg/m
2) 22.6  0.13 24.5  0.13 26.8  0.16 31.1  0.28
Waist circumference (cm) 80.5  0.38 86.2  0.39 93.2  0.40 103.8  0.62
Waist-to-hip ratio 0.85  0.003 0.88  0.004 0.92  0.003 0.96  0.003
Serum total cholesterol (mg/dl) 189  1.7 201  1.6 207  1.4 214  1.3
Serum HDL cholesterol (mg/dl) 57.0  0.74 52.8  0.73 48.5  0.57 43.7  0.65
Serum triglycerides (mg/dl) 88  2.3 112  3.3 137  3.1 178  3.5
Systolic blood pressure (mmHg) 112  0.6 115  0.6 119  0.6 124  0.8
Diastolic blood pressure (mmHg) 69.0  0.52 70.9  0.39 73.6  0.44 76.3  0.48
Physical activity intensity (MET)† 132  7.0 128  7.1 108  5.3 96  6.5
Daily coffee intake (cup) 1.44  0.113 1.22  0.100 1.22  0.077 1.22  0.079
Women (%) 58.0  2.2 55.7  2.2 47.6  2.1 48.7  2.1
Ethnicity (%)
Non-Hispanic white 83.2  1.7 80.7  1.5 78.2  1.4 71.0  2.1
Non-Hispanic black 7.5  0.78 8.1  0.68 10.2  0.81 12.6  1.0
Mexican American 3.8  0.54 3.7  0.43 4.3  0.51 7.3  0.85
Other 5.4  1.1 7.4  1.3 7.3  1.0 9.1  1.8
Cigarette smoking (%)
Never 45.7  1.9 48.9  2.2 46.9  1.6 42.3  2.4
Former 19.3  1.7 23.1  1.9 27.7  1.6 34.6  2.5
Less than one pack per day 15.3  2.1 10.7  1.5 10.3  1.3 10.6  1.3
One or more packs per day 19.7  1.9 17.3  1.7 15.1  1.4 12.5  1.7
Alcohol consumption (%)
None to 12 drinks per year 34.5  2.7 40.0  2.4 41.2  1.7 56.2  2.3
12 drinks per year–1 drink per day 47.1  2.5 44.6  2.5 44.9  2.1 31.3  2.1
1–2 drinks per day 11.0  1.3 7.7  1.2 7.7  1.1 8.3  1.4
2 drinks per day 7.4  1.0 7.7  1.0 6.2  1.1 4.1  0.8
C-reactive protein (%)
0–0.3 mg/dl 86.7  1.6 79.6  1.5 75.8  2.4 56.4  2.5
0.3 mg/dl 13.3  1.6 20.4  1.5 24.2  2.4 43.6  2.5
Data are means or proportions  SE. *Results adjusted for sampling and weighting processes of NHANES III to reﬂect estimates for the U.S. population. †Sum of
the products of activity frequency in the previous month and an intensity rating for nine common activities.
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jects in the second, third, and fourth
quartile of HOMA-IR appeared to have a
higher cardiovascular mortality risk than
subjects in the lowest quartile of
HOMA-IR (Table 3). There did not ap-
pear to be a “linear” relationship between
HOMA-IR and cardiovascular mortality;
rather, the risk appeared uniformly ele-
vated in the three higher quartiles relative
to the bottom quartile. When modeled as
a linear continuous variable, HOMA-IR
was not signiﬁcantly associated with car-
diovascular mortality (AHR 1.06 [95% CI
0.98–1.2]).
We investigated the association be-
tweeneachofthecomponentsofHOMA-IR
(plasma glucose and serum insulin) and
mortality (Table 4). Fasting plasma glucose
was not associated with mortality. Higher
serum insulin appeared to be associated
with mortality, but this association did not
reach statistical signiﬁcance.
CONCLUSIONS — HOMA-IR, a
marker of insulin resistance, was inde-
pendently associated with increased all-
Table 2—The association between HOMA-IR and all-cause mortality
Age- and sex-adjusted
HR (95% CI)
Multivariate-adjusted
HR (95% CI)*
Multivariate-adjusted
HR (95% CI)†
HOMA-IR
1.4 1 1 1
1.4–2.0 1.13 (0.8–1.6) 1.19 (0.8–1.7) 1.30 (0.9–1.9)
2.0–2.8 1.15 (0.8–1.6) 1.30 (0.9–1.9) 1.37 (0.9–2.0)
2.8 1.31 (0.9–1.9) 1.54 (1.1–2.2) 1.64 (1.1–2.5)
HOMA-IR: comparing successive quartiles 1.09 (1.0–1.2) 1.15 (1.01–1.3) 1.16 (1.01–1.3)
HOMA-IR: comparing subjects with a
HOMA-IR difference of 1 1.05 (1.0–1.11) 1.07 (1.02–1.11) 1.06 (1.02–1.1)
Participants with BMI 25.3 kg/m
2
HOMA-IR
1.4 1 1 1
1.4–2.0 1.15 (0.7–1.8) 1.15 (0.7–1.8) 1.33 (0.8–2.2)
2.0–2.8 1.47 (0.9–2.4) 1.47 (0.9–2.4) 1.73 (1.1–2.8)
2.8 1.60 (1.1–2.4) 1.65 (1.1–2.4) 1.86 (1.1–3.0)
HOMA-IR: comparing successive quartiles 1.19 (1.02–1.4) 1.19 (1.04–1.4) 1.25 (1.1–1.5)
HOMA-IR: comparing subjects with a
HOMA-IR difference of 1 1.19 (1.02–1.4) 1.20 (1.03–1.40) 1.26 (1.1–1.5)
Participants with BMI 25.3 kg/m
2
HOMA-IR
1.4 1 1 1
1.4–2.0 1.18 (0.6–2.3) 1.17 (0.6–2.2) 0.99 (0.5–1.8)
2.0–2.8 1.03 (0.6–1.9) 1.03 (0.6–1.9) 0.91 (0.5–1.6)
2.8 1.38 (0.7–2.7) 1.34 (0.7–2.6) 1.13 (0.6–2.2)
HOMA-IR: comparing successive quartiles 1.12 (0.9–1.3) 1.10 (0.9–1.3) 1.07 (0.9–1.3)
HOMA-IR: comparing subjects with a
HOMA-IR difference of 1 1.06 (1.0–1.1) 1.06 (1.0–1.1) 1.04 (0.9–1.1)
Men
HOMA-IR
1.4 1 1 1
1.4–2.0 1.02 (0.5–1.9) 1.19 (0.6–2.3) 1.25 (0.7–2.3)
2.0–2.8 1.14 (0.7–1.8) 1.51 (0.9–2.5) 1.77 (1.1–2.7)
2.8 1.23 (0.7–2.1) 1.72 (1.0–3.0) 1.87 (1.1–3.3)
HOMA-IR: comparing successive quartiles 1.08 (0.9–1.3) 1.20 (1.03–1.4) 1.24 (1.05–1.5)
HOMA-IR: comparing subjects with a
HOMA-IR difference of 1 1.04 (0.9–1.1) 1.06 (1.01–1.12) 1.05 (1.0–1.10)
Women
HOMA-IR
1.4 1 1 1
1.4–2.0 1.25 (0.8–2.0) 1.28 (0.8–2.0) 1.52 (0.9–2.5)
2.0–2.8 1.14 (0.7–1.8) 1.16 (0.7–1.9) 1.21 (0.7–2.0)
2.8 1.41 (0.9–2.2) 1.52 (0.9–2.6) 1.62 (0.9–3.0)
HOMA-IR: comparing successive quartiles 1.10 (1.0–1.2) 1.12 (0.95–1.3) 1.12 (0.93–1.36)
HOMA-IR: comparing subjects with a
HOMA-IR difference of 1 1.07 (0.99–1.15) 1.08 (0.99–1.16) 1.08 (0.99–1.2)
*Adjusted for age, sex, insulin resistance, BMI, and waist-to-hip ratio. †Adjusted for age, sex, insulin resistance, BMI, waist-to-hip ratio, race/ethnicity, smoking,
alcohol consumption, physical activity, education, systolic blood pressure, diastolic blood pressure, total serum cholesterol, serum HDL cholesterol, serum
triglycerides, and serum C-reactive protein.
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adjusting for measures of obesity, includ-
ing BMI and waist-to-hip ratio, and other
common predictors of mortality that
might also be associated with insulin re-
sistance. The association between
HOMA-IR and mortality was observed
only among people with normal BMI (be-
low the median level of 25.2 kg/m
2) but
not among people with a BMI 25.2
kg/m
2.
Insulin resistance estimated by
HOMA-IRwaspreviouslyassociatedwith
increased coronary events and all-cause
mortality among nondiabetic adults in
Malmo, Sweden (19). Insulin resistance
was also shown to be predictive of in-
creased mortality in certain high-risk
populations, including patients with dia-
betes (20), congestive heart failure (21),
and end-stage renal disease (22). In addi-
tion, Balkau et al. (23) showed increased
all-cause mortality in nondiabetic Euro-
pean men with hyperglycemia (upper
20% of 2-h glucose level after an oral glu-
cose tolerance test). However, we found
nootherstudieslinkinginsulinresistance
estimated by HOMA-IR to all-cause mor-
talityinnondiabeticindividualsrepresen-
tative of the U.S. population. There are
severalstudiesevaluatingtherelationship
between insulin resistance and cardiovas-
cular disease showing an increased risk of
Table 3—The association between HOMA-IR and cardiovascular or cancer mortality
Age- and sex-adjusted
HR (95% CI)
Multivariate-adjusted
HR (95% CI)*
Multivariate-adjusted
HR (95% CI)†
Cardiovascular mortality
HOMA-IR
1.4 1 1 1
1.4–2.0 3.0 (1.7–5.3) 3.1 (1.8–5.4) 3.7 (2.0–6.9)
2.0–2.8 2.0 (1.1–3.8) 2.2 (1.2–3.9) 2.6 (1.3–5.2)
2.8 2.4 (1.4–4.2) 2.5 (1.4–4.3) 3.2 (1.7–5.9)
HOMA-IR: comparing successive quartiles 1.13 (0.98–1.3) 1.15 (0.99–1.3) 1.21 (1.03–1.4)
HOMA-IR: comparing subjects with a
HOMA-IR difference of 1 1.06 (0.98–1.2) 1.05 (0.97–1.1) 1.06 (0.98–1.2)
Cancer mortality
HOMA-IR
1.4 1 1 1
1.4–2.0 0.59 (0.3–1.05) 0.63 (0.4–1.1) 0.62 (0.3–1.2)
2.0–2.8 0.88 (0.6–1.4) 1.0 (0.6–1.7) 0.83 (0.5–1.5)
2.8 0.95 (0.6–1.5) 1.2 (0.7–2.1) 0.90 (0.4–1.8)
HOMA-IR: comparing successive quartiles 1.04 (0.9–1.2) 1.11 (0.9–1.4) 1.01 (0.8–1.3)
HOMA-IR: comparing subjects with a
HOMA-IR difference of 1 0.99 (0.9–1.1) 1.01 (0.9–1.2) 0.94 (0.8–1.2)
*Adjusted for age, sex, insulin resistance, BMI, and waist-to-hip ratio. †Adjusted for age, sex, insulin resistance, BMI, waist-to-hip ratio, race/ethnicity, smoking,
alcohol consumption, physical activity, education, systolic blood pressure, diastolic blood pressure, total serum cholesterol, serum HDL cholesterol, serum
triglycerides, and serum C-reactive protein.
Table 4—The association between the components of HOMA-IR (fasting serum insulin and fasting plasma glucose) and all-cause mortality
Age- and sex-adjusted
HR (95% CI)
Multivariate-adjusted
HR (95% CI)*
Multivariate-adjusted
HR (95% CI)†
Fasting plasma glucose
89 1 1 1
89–94 0.77 (0.5–1.1) 0.78 (0.5–1.2) 0.76 (0.5–1.2)
94–100 0.65 (0.4–1.0) 0.66 (0.5–1.0) 0.66 (0.4–1.0)
100 0.94 (0.6–1.4) 0.96 (0.6–1.4) 0.95 (0.6–1.5)
Fasting plasma glucose: comparing successive quartiles 1.0 (0.9–1.2) 1.0 (0.9–1.2) 1.0 (0.9–1.2)
Linear fasting plasma glucose: comparing subjects with
a fasting plasma glucose difference of 1 1.0 (0.99–1.01) 1.0 (0.99–1.01) 1.0 (0.99–1.01)
Fasting serum insulin
6.15 1 1 1
6.15–8.35 1.01 (0.7–1.4) 1.08 (0.8–1.5) 1.16 (0.8–1.6)
8.35–11.5 1.19 (0.9–1.6) 1.34 (0.9–2.0) 1.40 (0.9–2.1)
11.5 1.23 (0.9–1.7) 1.43 (1.0–2.1) 1.48 (0.9–2.2)
Fasting serum insulin: comparing successive quartiles 1.08 (0.98–1.2) 1.14 (1.0–1.3) 1.14 (0.99–1.31)
Linear fasting plasma insulin: comparing subjects with
a fasting serum insulin difference of 1 1.01 (0.99–1.03) 1.02 (1.0–1.03) 1.02 (1.0–1.03)
*Adjusted for age, sex, BMI, and waist-to-hip ratio. †Adjusted for age, sex, BMI, waist-to-hip ratio, race/ethnicity, smoking, alcohol consumption, physical activity,
education, systolic blood pressure, diastolic blood pressure, total serum cholesterol, serum HDL cholesterol, serum triglycerides, and serum C-reactive protein.
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diovascular events in both patients with
(1) and without (24) a previous history of
coronary artery disease.
Insulin resistance is strongly associ-
ated with measures of obesity, such as
BMI and waist-to-hip ratio. In fact, excess
adiposity is considered a major cause of
insulin resistance. However, we found
that insulin resistance is associated with
mortalityevenafteradjustingforBMIand
waist-to-hip ratio. Furthermore, a novel
and surprising ﬁnding of our study was
that insulin resistance was independently
associated with mortality only among in-
dividuals with a normal BMI (below the
median level of 25.2 kg/m
2). In these in-
dividuals, insulin resistance is presum-
ably caused by factors other than obesity,
as deﬁned by elevated BMI. Therefore,
our ﬁndings suggest that high BMI–
related insulin resistance does not confer
an independent, excess risk of mortality.
On the other hand, low BMI–related in-
sulin resistance is independently associ-
ated with mortality. In support of this
ﬁnding, hyperinsulinemia has been asso-
ciated with a more marked increase in in-
ﬂammatory cytokines (speciﬁcally
interleukin-6) among healthy subjects
with normal BMI when compared with
diabetic subjects with an overweight BMI
(25). Future studies should investigate
further the systematic differences be-
tween insulin-resistant individuals with
high BMI and insulin-resistant individu-
als with low BMI.
Table 4 suggests that the association
between HOMA-IR and mortality that we
describe is driven primarily by the associ-
ation between serum insulin and mortal-
ity. There was no association between
fasting plasma glucose (the other compo-
nent of HOMA-IR) and mortality in these
nondiabetic subjects. The magnitude of
the associations between quartiles of
HOMA-IR and mortality was greater than
the magnitude of the associations between
serum insulin and mortality. This suggests
that improved prediction of mortality
would be expected by using HOMA-IR
rather than just using serum insulin.
In secondary analyses, we identiﬁed
that HOMA-IR was associated with car-
diovascularmortalitybutnotcancermor-
tality. We did not identify a trend of
increasing cardiovascular mortality with
increasing HOMA-IR category. Rather, it
appeared that subjects in the top three
quartiles of insulin resistance had uni-
formly elevated mortality relative to sub-
jects in the lowest quartile. When
modeled as a linear variable, HOMA-IR
was not signiﬁcantly associated with car-
diovascular mortality (AHR 1.06 [95% CI
0.98–1.2]). However, the cause of death
in our study was identiﬁed from death
certiﬁcates that may be inaccurate and
therefore masking any real trends in car-
diovascular mortality with increasing
HOMA-IR. While ascertainment of cause
of death might have been subject to some
inaccuracy, vital status and date of death
wereveryaccuratelyascertained(99%).
Thus, our results on the association be-
tween HOMA-IR and all-cause mortality
are expected to be accurate and valid and
constitute our study’s primary outcome.
Future studies should explore further the
associations between insulin resistance
and cause-speciﬁc mortality with better
ascertainmentofthecauseofdeath.Atthe
same time, our study has considerable
strengths. HOMA-IR was measured in a
large sample representative of the U.S.
population. Follow-up duration was ade-
quate and ascertainment of mortality was
accurate and performed without rele-
vance to baseline HOMA-IR level.
HOMA-IR is associated with mortal-
ity in the U.S. population particularly
among individuals with normal BMI.
HOMA-IR is a readily available measure
that can be used in the future to predict
mortality in clinical or epidemiological
settings. The distinction between the im-
plications of elevated HOMA-IR in sub-
jects with normal BMI versus elevated
BMI deserves further investigation and
may shed light on the pathophysiology of
insulin resistance and its consequences.
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